Medical News, Journals & Upcoming Events
Most Read Psychiatry Articles on JAMA Network
- Suicide Mortality Association With Bipolar Disorder Rates in Swedish Adolescents May 24, 2023This cross-sectional study uses national Swedish registry data to assess regional associations of bipolar disorder diagnosis rates and suicide mortality in adolescents.
- COVID-19 and Risk for Mental Disorders After SARS-CoV-2 PCR Testing in Denmark May 24, 2023This nationwide cohort study assesses the association of SARS-CoV-2 infection and subsequent risk of mental disorders and use of psychotropic medication among the adult population of Denmark.
- Cannabis Use Disorder and Subsequent Risk of Unipolar Depression and Bipolar Disorder May 24, 2023This cohort study investigates the association of cannabis use disorder with risk of psychotic or nonpsychotic unipolar depression and bipolar disorder in Denmark.
- Global Mental Health Services and AI-Powered Language Models May 17, 2023This Viewpoint describes ways in which artificial intelligence–powered large language models may be used to improve the delivery of mental health services worldwide.
- Associations Between Psychopathology Factors and 10-Year Clinically Relevant Outcomes in Adult Swedish Twins and Siblings May 10, 2023This cohort study evaluates the association between psychopathology factors and clinically relevant outcomes at 10 years among twins and siblings.
JAMA Oncology Current Issue
- JAMA Oncology Peer Reviewers in 2022 May 18, 2023We sincerely thank the 866 peer reviewers who completed manuscript reviews for JAMA Oncology in 2022.
- Change of Article Status to Open Access May 1, 2023The Original Investigation titled “Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: the FAST-01 Nonrandomized Trial,” published in the January 2023 issue of JAMA Oncology, has changed license status to open access (CC-BY-NC-ND license). This article was updated online.
- Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers May 1, 2023This Viewpoint discusses the role of data interpretation and clinical trial design in improving therapy of neuroendocrine cancers.
- Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply May 1, 2023In Reply We would like to thank Reid et al for their valuable comments on our cohort study in which we demonstrated an association between dual immune checkpoint inhibitors (ICIs) and impaired survival in patients with grade 3 or higher immune-related adverse events (irAEs) who received second-line immunosuppressants compared with those who only received corticosteroids. […]
Upcoming Events
To receive information about upcoming events and the latest CE Activities, join our network.
